INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 100 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2016 | $0 | -100.0% | 154 | -88.2% | 0.00% | – |
Q2 2016 | $2,000 | -50.0% | 1,300 | +160.0% | 0.00% | – |
Q4 2015 | $4,000 | -77.8% | 500 | -75.5% | 0.00% | – |
Q3 2015 | $18,000 | +100.0% | 2,041 | +155.1% | 0.00% | – |
Q2 2015 | $9,000 | -98.3% | 800 | -97.9% | 0.00% | -100.0% |
Q1 2015 | $523,000 | – | 37,368 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |